Vuksan Vladimir, Sievenpiper John L
Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Canada.
Nutr Metab Cardiovasc Dis. 2005 Jun;15(3):149-60. doi: 10.1016/j.numecd.2005.05.001.
The only example of an approved antidiabetic drug that was developed from a herbal source with a long history of use for diabetes is the biguanide Metformin from French lilac (Galega officinalis). Clinical data are beginning to emerge that support antidiabetic indications for several other herbs. This viewpoint discusses the state of the evidence for their clinical antidiabetic efficacy. One of the most studied herbs, ginseng (Panax spp.), is used as a model to illustrate the challenges associated with achieving reproducible clinical efficacy. It is concluded that the best evidence for clinical efficacy in diabetes remains for ginseng. But overall insufficient evidence exists to claim a diabetes indication for herbs. The experience with ginseng suggests that although reproducible efficacy may be achieved using an acute postprandial clinical screening model to select an efficacious ginseng batch, dose, and time of administration, there is a need to develop a basis for standardization that ties the composition of herbs to efficacy. In absence of such standardization, the use of herbs in diabetes must be approached cautiously.
唯一一种从有悠久糖尿病治疗历史的草药来源开发出来的已获批抗糖尿病药物是源自紫花洋地黄(山羊豆)的双胍类药物二甲双胍。支持其他几种草药具有抗糖尿病适应证的临床数据正开始出现。本文观点讨论了其临床抗糖尿病疗效的证据状况。人参(人参属)是研究最多的草药之一,被用作一个模型来说明在实现可重复的临床疗效方面所面临的挑战。得出的结论是,人参在糖尿病临床疗效方面的证据最为充分。但总体而言,尚无足够证据支持草药具有糖尿病适应证这一说法。人参的经验表明,尽管使用急性餐后临床筛选模型来选择有效的人参批次、剂量和给药时间可能会实现可重复的疗效,但仍需要建立一种将草药成分与疗效联系起来的标准化基础。在缺乏这种标准化的情况下,糖尿病患者使用草药必须谨慎。